Given that inheritance of a BRCA1 or BRCA2 mutation correlates with earlier onset of disease, aggressive tumor behavior, and heightened recurrence risk, targeted therapies such as oral poly(ADP-ribose) polymerase (PARP) inhibitors offer potential additional treatments for these patients (40). Here, BRCA1 is linked to neoplasm.